Wedbush analyst Liana Moussatos reiterated an Outperform rating on shares of Relypsa Inc (NASDAQ:RLYP), with a $51 price target, after hosting an expert call with a key opinion leader (KOL) nephrologist to discuss hyperkalemia treatments.
Moussatos noted, “KOL views Veltassa as best-in-class for hyperkalemia. Primarily due to Veltassa’s use of calcium instead of ZS-9’s use of sodium as a counter ion, Dr. Weir views Veltassa as best-in-class for chronic hyperkalemia treatment and has no plans to use ZS-9 for chronic hyperkalemia due to sodium related toxicities such as edema and hypertension. He sees Veltassa as having potential expansion into dialysis and transplant patients developing hyperkalemia.”
“Dr. Weir was adamant about not prescribing a drug that elevates sodium in CKD and heart failure patients— especially chronically—and consequently he has no plans to use ZS-9 (since Veltassa is available) […] We continue to wait for the long-term ZS-9 treatment results from the ZS-004 study which completed in mid-2015 (NCT02107092). We anticipate equal or higher edema and hypertension rates than the approximately 7-7.7% seen from interim results,” the analyst added.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Liana Moussatos has a yearly average return of 8.9% and a 38% success rate. Moussatos has an -5.3% average return when recommending RLYP, and is ranked #333 out of 3990 analysts.
Out of the 10 analysts polled by TipRanks (in the past 3 months), 8 rate Relypsa stock a Buy, 1 rates the stock a Hold and 1 recommends a Sell. With a return potential of 61%, the stock’s consensus target price stands at $30.56.
Mast Therapeutics Inc
Maxim analyst Jason McCarthy weighed in today on Mast Therapeutics Inc (NYSEMKT:MSTX) after the biotch company announced expansion of IP for vepoloxamer with the receipt of notice of allowance of a composition of matter patent was approved by the USPTO.
McCarthy stated, “With a potential approval in sickle cell (pending data this summer), Mast is taking the necessary steps to build IP around what could be only the second drug approved for sickle cell in the past 50 years and the only drug approved to treat the most common manifestation of the disease…pain crisis.”
McCarthy reiterated a Buy rating on Mast Therapeutics, with a $5 price target, which implies a huge upside of 1199% from current levels.
According to TipRanks.com, analyst Jason McCarthy has a yearly average return of 9.6% and a 55% success rate. McCarthy has a 23% average return when recommending MSTX, and is ranked #351 out of 3990 analysts.
Shareholders of SCYNEXIS Inc (NASDAQ:SCYX) are having a rough day as the company’s stock is down by 23%, after the drug maker announced top-line results from its Phase 2a pilot trial of SCY-078 in Acute Vulvovaginal Candidiasis (VVC). There was a higher incidence of adverse effects with SCY-078 (88%) compared to fluconazole (13%). However, no patients discontinued and no serious adverse events were observed.
Needham analyst Alan Carr noted, “We believe that the current SCY-078 regimens will allow room to explore optimal doses that normalize the GI adverse effects while maintaining efficacy. The company will consider different dosages as well as different administration duration, and plans to start a dose-finding Phase 2 trial in acute VVC in a larger patient population to address the high rate of GI events. Beyond VVC, we expect the company to complete enrollment of its Phase 2 IC trial in June with top-line results expected a few weeks later in July. Also expected in 3Q16 are results from the Phase 1 trial of intravenous SCY-078, and identification of an optimal IV formulation will allow SCYNEXIS to start its registration program as planned in 4Q16 (the treatment refractory trial) and 1H17 (the registration IC trial).”
Carr rates SCYX stock a Buy with a price target of $16, which implies an upside of 408% from current levels.
According to TipRanks.com, analyst Alan Carr has a yearly average return of 13.8% and a 50% success rate. Carr has a -24.4% average return when recommending SCYX, and is ranked #121 out of 3990 analysts.